Histological activity (Oxford MEST‐C scores), persistent microhematuria (>20 RBC/HPF), and biomarkers like galactose‐deficient IgA1 or urinary sCD163 provide nuanced insights into progression risk. This evidence concerns the gene IGHA1 and Microscopic hematuria.